$42.55
Value $5.5B
CON and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$42.55
Value $5.5B
$147.76
Value $365B
Concentra Group Holdings Parent (CON) has a market value of $5.5B and Merck & Company (MRK) $365B. Over the last year, with dividends, CON moved +115.4% and MRK +66.3%. The P/E is 25.8 for CON and 148.9 for MRK. Dividend yield: CON 0.59%, MRK 2.30%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CON$5.5B
MRK$365B
MRK is 67 times CON
Revenue, 12 months
CON$2.3B
MRK$67.4B
MRK is 29 times CON
Net income, 12 months
CON$216M
MRK$2.5B
MRK is 11 times CON
Operating margin
CON16.9%
MRK–
ROIC
CON15.1%
MRK3.9%
11.2 points apart
P/E
CON25.8
MRK148.9
MRK is 5.8 times CON
Dividend yield
CON0.6%
MRK2.3%
1.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CON+115.4%
MRK+66.3%
| Period | CONWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +115.4%Price +113.2% | +66.3%Price +61.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CONConcentra Group Holdings ParentMRKMerck & Company
| Price | $42.55 | $147.76 |
|---|---|---|
| Market value | $5.5B | $365B |
| Enterprise value (EV) | $6.9B | $409B |
| P/E | 25.8 | 148.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 10.8 | 8.1 |
| EV/EBIT | 17.5 | 86.0 |
| Free cash flow yield | 4.7% | 4.0% |
| Revenue, 12 months | $2.3B | $67.4B |
|---|---|---|
| Net income, 12 months | $216M | $2.5B |
| Free cash flow, 12 months | $257M | $14.7B |
| Earnings per share, 12 months | $1.69 | $0.98 |
| Revenue growth, year on year | 13.9% | 1.3% |
| Revenue growth a year, past | +7.9%over 3 years | +9.4%over 5 years |
| EPS growth a year, past | -6.7%over 3 years | +21.2%over 5 years |
| Gross margin | 29.9% | 71.8% |
|---|---|---|
| Operating margin | 16.9% | – |
| Net margin | 9.3% | 3.6% |
| ROIC | 15.1% | 3.9% |
| ROE | 49.5% | 5.2% |
| Cash | $86M | $9.7B |
|---|---|---|
| Total debt | $2.1B | $53.8B |
| Net debt / EBITDA | 3.1 | 5.7 |
| Interest cover | 3.6× | 2.4× |
| Dividend yield | 0.6% | 2.3% |
|---|---|---|
| Dividend per share, 12 months | $0.25 | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 0.4% | 1.4% |
| Shareholder yield | 1.0% | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($365B) is about 66.7 times Concentra Group Holdings Parent ($5.5B), at today's prices.
Since November 12, 2025, CON's price moved +113.2% and MRK's +61.6%. With dividends: CON +115.4% (+115.4% a year), MRK +66.3% (+66.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.59% for Concentra Group Holdings Parent and 2.30% for Merck & Company. Over the last twelve months they paid $0.25 and $3.40 per share.
At today's price, the P/E is 25.8 for CON and 148.9 for MRK. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.3% for Concentra Group Holdings Parent and 3.6% for Merck & Company, and the operating margin 16.9% and –. Revenue was $2.3B and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.